Erythroleukemia in a renal transplant recipient

Area of Science:

• Nephrology
• Hematology
• Oncology

Background:

• Renal transplantation requires long-term immunosuppressive therapy.
• Azathioprine is a commonly used immunosuppressant medication.
• Immunosuppression is associated with an increased risk of certain malignancies.

Observation:

• A 53-year-old male developed acute erythroleukemia three years post-renal transplant.
• The patient had a history of three years of azathioprine therapy.
• A preleukemia phase with chromosomal abnormalities was identified prior to leukemia diagnosis.

Findings:

• Azathioprine is known to cause chromosomal abnormalities.
• The immunosuppressive therapy may have contributed to the development of leukemia.
• Chronic stimulation of abnormal erythroid clones by transplantation could accelerate leukemogenesis.

Implications:

• Azathioprine use warrants careful monitoring for hematologic malignancies in transplant recipients.
• Understanding the link between immunosuppression and leukemia is crucial for patient management.
• Further research into the mechanisms of azathioprine-induced leukemogenesis is needed.